Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

$ 1,701 $ - $ 6,401 $ - Operating expenses Research and development 3,079 3,588 9,459 5,282 General and administrative 1,475 1,003 2,825 1,785 Total operating expenses 4,554 4,591 12,284 7,067 Other income (expense) 7 34 (7) 91 Loss for the period before taxes 2,846 4,557 5,890 6,976 Income tax expense (recovery) (3,000) 6 (3,000) (4) Net income (loss) $ 154 ($ 4,563) ($ 2,890) ($ 6,972) Condensed Consolidated Balance Sheets (in thousands) June 30, December 31, 2010 2009 (unaudited) Assets: Cash, cash equivalents and short term investments $ 47,304 $ 64,568 Restricted cash 502 - Amounts receivable 413 3,109 Prepaid and other current assets 2,341 722 Property, equipment and other assets 582 581 ------------------------ Total assets 51,142 $ 68,980 ------------------------ ------------------------ Liabilities and stockholders' equity: Accounts payable and accrued expenses 1,667 $ 14,453 Deferred collaboration revenue 24,135 26,528 Other current liabilities 1,278
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Asia-Pacific , and Rest of ... 2012 through 2020. Market data and analytics are derived from ...
(Date:8/19/2014)... Aug. 19, 2014 Research ... of the "Spectroscopy Equipment and Accessories ... to their offering. This ... Equipment and Accessories in US$ Thousands by ... spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared ...
(Date:8/19/2014)... Md. , Aug. 19, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today that its novel ... at the 54 th Interscience Conference on ... Washington D.C. ...
(Date:8/18/2014)... Dallas, Texas (PRWEB) August 19, 2014 ... China Linalool Industryā€¯ is a professional and in-depth ... report provides basic Linalool information, including its ... well as industry overview. This research covers the ... well as global industry analysis covering macroeconomic environment ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4
... ANNAPOLIS, Md., May 7 /PRNewswire-FirstCall/ -- PharmAthene, ... company developing medical countermeasures against biological and chemical threats, ... quarter of 2009 will be released on Thursday, May ... to discuss its first quarter 2009 financial results. ...
... fuels provider New Generation Biofuels Holdings, Inc. (Nasdaq: ... has signed a contract with the City of Baltimore, Maryland,("the ... for boiler applications in the heart of Baltimore. This is ... non fossil fuel in its industrial boilers. In this program, ...
... May 7 Covance Inc. (NYSE: CVD ... its board of directors. Mr. McCartney currently serves as ... provider of specialty products, services, and supply chain solutions. ... of U.S. Robotics (USR), a multibillion dollar provider of ...
Cached Biology Technology:City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications 2City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications 3Covance Elects John McCartney to Company's Board of Directors 2
(Date:8/19/2014)... Plants are superior to humans and animals in a ... regenerate, which enables them to regrow entire organs. After ... grow back its entire crown. But there is one ... quite literally rooted to the habitats in which they ... elements. In response to this dilemma, plants have developed ...
(Date:8/19/2014)... to treat pain, but its effect on pain ... a recent study reported on the Neural ... rat models of an avulsion injury to the ... neuropathic pain) were given electroacupuncture stimulation at bilateral ... (GB34). After electroacupuncture therapy, chronic neuropathic pain in ...
(Date:8/19/2014)... news release is available in German . ... get new information about the metabolism of plants can ... However, Erich Kombrink from the Max Planck Institute for ... the University of Duisburg-Essen adopt a different approach. They ... metabolic process like brake pads and prevent the downstream ...
Breaking Biology News(10 mins):How steroid hormones enable plants to grow 2Researchers block plant hormone 2Researchers block plant hormone 3
... cases of Marburg haemorrhagic fever have been reported in ... reported its first 6 cases, bringing the number of ... part of the country. , Mobile surveillance teams in ... were attacked and damaged by local residents. As the ...
... provide a method of quantifying the expression and order of ... measure of cell physiology, said researchers at Baylor College of ... journal Nature Genetics. , "Microarray data are good phenotypes to ... measure of cell status," said Dr. Gad Shaulsky, associate professor ...
... administration to improve patient compliance and reduce drug side ... healthcare product category. While quietly gaining market share for ... and HRT, the technology is set to make further ... conditions wind their way through the development and clinical ...
Cached Biology News:WHO suspends Marburg work, appeals for new funds 2Microarrays as phenotype 2
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
MDMA Mouse Monoclonal Antibody (Clone 3G8)...
Biology Products: